Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
- Shekoufeh Nikfar
- , Abbas Kebriaeezadeh
- , Rassoul Dinarvand
- , Mohammad Abdollahi
- , Mohammad Ali Sahraian
- , David Henry
- , Ali Akbari Sari*
*Corresponding author for this work
Research output: Contribution to journal › Article › Research › peer-review
36
Link opens in a new tab
Citations
(Scopus)